|
Aug. 04, 2023 |
|
|
Oct. 06, 2025 |
|
|
jRCT2011230029 |
33-104 : Drug Use-Results Survey of OPDIVO (Unresectable advanced/recurrent malignant pleural mesothelioma that has progressed after cancer chemotherapy) |
|
33-104 : Drug Use-Results Survey of OPDIVO |
Nakao Takafumi |
||
Ono Pharmaceutical Co.,LTD |
||
1 -5 Doshomachi 2-chome, Chuo-ku, Osaka-shi, Osaka 541-8526, Japan |
||
+81-6-6222-5501 |
||
pms_contact_ml@ono-pharma.com |
||
Nakao Takafumi |
||
Ono Pharmaceutical Co.,LTD |
||
1 -5 Doshomachi 2-chome, Chuo-ku, Osaka-shi, Osaka 541-8526, Japan |
||
+81-6-6222-5501 |
||
pms_contact_ml@ono-pharma.com |
Complete |
Nov. 01, 2018 |
||
| Dec. 18, 2018 | ||
| 100 | ||
Observational |
||
single arm study |
||
open(masking not used) |
||
uncontrolled control |
||
single assignment |
||
other |
||
Patients with unresectable advanced/recurrent malignant pleural mesothelioma that has progressed after cancer chemotherapy, who have recieved OPDIVO for the first time |
||
Patients who have received OPDIVO previously |
||
| No limit | ||
| No limit | ||
Both |
||
Unresectable advanced/recurrent malignant pleural mesothelioma that has progressed after cancer chem |
||
[Safety] |
||
| Ono Pharmaceutical Co.,LTD |
| Not being included in the items required by GPSP Ordinance, a central IRB is not in place. The study is planned to conduct an IRB at the study site as needed. | |
| none, Hokkaido | |
Nov. 15, 2018 |
No |
none |